The Team
PhD. Göran Ronquist
Founder and board member
As a prominent chemist and researcher, Göran is the core of Ambusol’s research and development. Göran has previously worked as a researcher at Oblique Therapeutics, SLU, and Uppsala University. Göran’s deep knowledge and passion for innovation are a vital part of Ambusol’s ongoing research and development.
Frederic Telander
Founder and chairman of the board
Frederic is a seasoned corporate leader and entrepreneur with financial background and over 30 years of experience in senior roles across both public and private companies. He has led IPOs in the UK and Sweden, including Gas Turbine Efficiency Plc, Soltech Energy, and Gigasun, where he currently serves as Chairman.
As Chairman of Ambusol, Frederic plays a key role in strategic financial planning and investor exit strategies. His leadership and extensive business acumen are vital to Ambusol’s continued growth and success.
Holger Ronquist
Founder and board member
International businessman with combined technical and legal expertise. Formerly held roles at Ericsson and within government agencies. At Ambusol, he supports client negotiations and regulatory approvals.
Maximilian Telander
CEO, founder and board member
With a solid financial background from Warwick Business School and experience at Deutsche Bank, he brings strong expertise to his role as CEO of Ambusol. His financial insight and strategic leadership play a key role in shaping the company’s business direction, strengthening its go-to-market plan, and supporting long-term growth.
Prof. Gunnar Ronquist
Founder and board member
Gunnar Ronquist is a physician and researcher with extensive experience in oncology and medical innovation. He is the founder of Ambusol, a company dedicated to developing innovative and non-toxic therapies for cancer. As a former senior physician at Uppsala University Hospital and a licensed practitioner in both Sweden and the United States, he brings a unique clinical and international background.
He is the inventor of Ambusol’s oncological treatment method and a pioneer in prostasome research, for which he was awarded the Royal Society of Science Award in 2014. Throughout his academic career, he supervised 35 PhD students and authored more than 360 scientific articles published in leading cancer research journals.
As former editor-in-chief of the Uppsala Journal of Medical Sciences and co-author of the book Biological Transport, he has contributed to advancing scientific discourse in medicine and biology. Today, he leads the development of Ambusol’s treatments and expands research into new cancer types, focusing on cost-effective, patient-centered, and quality-of-life–enhancing therapies.
